Light control of RTK activity: From technology development to translational research

Anna V. Leopold, Vladislav V. Verkhusha

Research output: Contribution to journalReview articlepeer-review

Abstract

Inhibition of receptor tyrosine kinases (RTKs) by small molecule inhibitors and monoclonal antibodies is used to treat cancer. Conversely, activation of RTKs with their ligands, including growth factors and insulin, is used to treat diabetes and neurodegeneration. However, conventional therapies that rely on injection of RTK inhibitors or activators do not provide spatiotemporal control over RTK signaling, which results in diminished efficiency and side effects. Recently, a number of optogenetic and optochemical approaches have been developed that allow RTK inhibition or activation in cells and in vivo with light. Light irradiation can control RTK signaling non-invasively, in a dosed manner, with high spatio-temporal precision, and without the side effects of conventional treatments. Here we provide an update on the current state of the art of optogenetic and optochemical RTK technologies and the prospects of their use in translational studies and therapy. This journal is

Original languageEnglish (US)
Pages (from-to)10019-10034
Number of pages16
JournalChemical Science
Volume11
Issue number37
DOIs
StatePublished - Oct 7 2020

ASJC Scopus subject areas

  • Chemistry(all)

Fingerprint Dive into the research topics of 'Light control of RTK activity: From technology development to translational research'. Together they form a unique fingerprint.

Cite this